Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Spondylitis, Ankylosing 1 Signs and Symptoms 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Glioma 1 Epilepsy 1 Diarrhea 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Sirolimus 4 LY3295668 erbumine 3 Everolimus 3 Anticonvulsants 2 perampanel 1 clevidipine 1 brivaracetam 1 Vigabatrin 1 Topotecan 1 Therapeutic Touch 1 Temozolomide 1 TAS-119 1 Sulfasalazine 1 Sevoflurane 1 Saline Solution 1 Radiotherapy 1 Propofol 1 Paclitaxel 1 Nitrous Oxide 1 Midazolam 1 Memantine 1 Medical Marijuana 1 Lidocaine 1 Levetiracetam 1 Ketamine 1 Immunoglobulins, Intravenous 1 Glycopyrrolate 1 Gabapentin 1 Fluid Therapy 1 Fentanyl 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Epilepsy × Sulfasalazine × Clear all

NCT05664464 2024-05-10

GLUGLIO

University of Zurich

Phase 1/2 Recruiting

Epilepsy, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡